PEPG$2.44+3.62%
PepGen Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$168.65M
Float & O/S:49.09M / 69.26M
Inst Own:75.2%
DilutionScan read 32 of PepGen Inc.'s SEC filings and found 2 ATM programs, 3 shelf registrations and 1 completed offering on file for PEPG. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
5d old
PEPG
Pre-revenue biotech burning cash, heavy dilution
- Business
- WeakNo revenue, $89.7M net loss, 18.3-month runway
- Stock risk
- HighShares +33.7% YoY, 57.2% overhead dilution, near 52w low
Snapshot
PepGen is a clinical-stage biotech with no revenue, developing treatments for a muscular disease currently in Phase 2 trials. FY 2025 net loss was $89.7M, roughly in line with prior years, and free cash flow was negative $81.9M.
What's Happening Right Now
- : On Oct 5, 2026, MarketBeat reported PepGen holds a 'Moderate Buy' consensus from six covering analysts, with five buy and one sell rating.
- : On Aug 6, 2026, PepGen reported a Q2 2026 net loss of $0.26 per share with $117.2 million in cash, which it says funds operations into Q4 2027.
- : On Aug 6, 2026, an independent safety board recommended advancing PepGen's Phase 2 FREEDOM2-DM1 study to the highest 12.5 mg/kg dose with no protocol changes, citing no serious adverse events; 10 mg/kg cohort data is expected in November and 12.5 mg/kg data in first half 2027.
- : Sold $1.50M net / 238K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.
- : Registered $400.00M of securities for sale on Form S-3.
- : Sold $1.51M net / 238K shares through its at-the-market program, as stated for Jan 1, 2026 to Mar 31, 2026.
